Guided View New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.
Expert View You already know the biology. Just the content, clean and compact, with no extra explanations. This is the default view.
Interface language
Light mode
Clinical trial · ATTR amyloidosis
MAGNITUDE-2: Phase 3 in vivo CRISPR for ATTR polyneuropathy
Official title: A Phase 3 Study of Nexiguran Ziclumeran in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy
PausedPhase IIINCT06672237
Clinical researchBeing tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
What this trial is testing
The companion Phase 3 study to MAGNITUDE, in people whose nerves rather than heart are affected by the same disease. It was paused alongside MAGNITUDE after the safety event in that trial.
A Phase 3 study of nexiguran ziclumeran in hereditary ATTR amyloidosis with polyneuropathy. Dosing and screening were paused alongside MAGNITUDE following the hepatic safety event, and the study was placed on clinical hold by the FDA.
What a trial result does and does not mean
Early-phase results come from small numbers of participants and short follow-up. They can change with more people and more time, and a trial that is recruiting, active or even completed has not established that a treatment works. Enrolment criteria are strict; eligibility is decided by the trial site, never by a website.
Written by CRISPR Decoded editorial teamLast updated Oct 27, 2026
Connected in CRISPR Decoded
Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.
This link opens a website we do not run. We cannot control its content, its accuracy, or how it handles your data, including its own cookies and tracking. Nothing you read there has been reviewed by us.